- Home
- FTEL vs BIAF Comparison
FTEL vs BIAF Comparison
Compare FTEL & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTEL
- BIAF
- Stock Information
- Founded
- FTEL 2007
- BIAF 2014
- Country
- FTEL Australia
- BIAF United States
- Employees
- FTEL N/A
- BIAF N/A
- Industry
- FTEL
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- FTEL
- BIAF Health Care
- Exchange
- FTEL Nasdaq
- BIAF Nasdaq
- Market Cap
- FTEL 11.1M
- BIAF 12.2M
- IPO Year
- FTEL 2023
- BIAF 2022
- Fundamental
- Price
- FTEL $0.54
- BIAF $0.27
- Analyst Decision
- FTEL
- BIAF Hold
- Analyst Count
- FTEL 0
- BIAF 1
- Target Price
- FTEL N/A
- BIAF N/A
- AVG Volume (30 Days)
- FTEL 190.3K
- BIAF 11.4M
- Earning Date
- FTEL 07-15-2025
- BIAF 08-13-2025
- Dividend Yield
- FTEL N/A
- BIAF N/A
- EPS Growth
- FTEL N/A
- BIAF N/A
- EPS
- FTEL N/A
- BIAF N/A
- Revenue
- FTEL $4,990,695.00
- BIAF $8,809,228.00
- Revenue This Year
- FTEL N/A
- BIAF N/A
- Revenue Next Year
- FTEL N/A
- BIAF $20.00
- P/E Ratio
- FTEL N/A
- BIAF N/A
- Revenue Growth
- FTEL 29.02
- BIAF 78.40
- 52 Week Low
- FTEL $0.36
- BIAF $0.16
- 52 Week High
- FTEL $49.50
- BIAF $2.99
- Technical
- Relative Strength Index (RSI)
- FTEL 54.43
- BIAF 47.98
- Support Level
- FTEL $0.47
- BIAF $0.26
- Resistance Level
- FTEL $0.52
- BIAF $0.36
- Average True Range (ATR)
- FTEL 0.05
- BIAF 0.05
- MACD
- FTEL 0.01
- BIAF 0.00
- Stochastic Oscillator
- FTEL 82.13
- BIAF 20.34
About FTEL Fitell Corporation
Fitell Corp engages in primary operations of selling gym and fitness equipment in Australia through its indirectly held wholly owned subsidiaries. It operates in two segments: online fitness equipment distribution and licensing business to service the large and growing boutique fitness sector of the broader health and fitness club industry. The majority fitness equipment business is conducted in Australia via its own e-commerce platform and, through third-party sites. Licensing service offers a turnkey solution for personal training studios and commercial gym chains. The company earns maximum of revenue for retail.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.